Bodet-Milin, C., Ferrer, L., Pallardy, A., Eugène, T., Rauscher, A., Faivre-Chauvet, A., Barbet, J., Kraeber-Bodéré, F. (2013) Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma. Front Oncol. 3, 177.

Carlier, T., Eugène, T., Bodet-Milin, C., Garin, E., Ansquer, C., Rousseau, C., Ferrer, L., Barbet, J., Schoenahl, F., Kraeber-Bodéré, F. (2013) Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Res. 3, 11.

Chérel, M., Gouard, S., Gaschet, J., Saï-Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J.F., Kraeber-Bodéré, F., Barbet, J., Moreau, P., Davodeau, F. (2013) 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. J. Nucl. Med. 54, 1597-1604.

Frampas, E., Rousseau, C., Bodet-Milin, C., Barbet, J., Chatal, J.F., Kraeber-Bodéré, F. (2013) Improvement of radioimmunotherapy using pretargeting. Front Oncol. 3, 159.

Laffon, E., Bardiès, M., Barbet, J., Marthan, R. (2013) Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value. EJNMMI Res. 3, 26.

Mauxion, T., Barbet, J., Suhard, J.M., Pouget, J.P., Poirot, M., Bardiès, M. (2013) Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med Phys. 40, 052501.

Rousseau, C., Kraeber-Bodéré, F., Barbet, J., Chatal, J.F. (2013) Pretargeted radioimmunotherapy : clinically more efficient than conventional radioimmunotherapy ? Eur J Nucl Med Mol Imaging. 40, 1373-1376.

Chatal JF, Barbet J, Kraber-Bodéré F, Goldenberg DM. Medullary Thyroid Carcinoma. In : Nuclear Medicine Therapy : Principles and clinical applications. C. Aktolun et S.J. Goldsmith (eds.), Springer Verlag+Business Media, New-York, 2013.

Barbet, J., Chatal, J.F. Cyclotron-based Radiopharmaceuticals for Nuclear Medicine Therapy. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.

Kraeber-Bodéré, F., Faivre-Chauvet, F., Bodet-Milin, C., Wegener, W.A., Chatal, J.F., Goldenberg, D.M. Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.